Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C von Colombo, M, Fernández, I, Abdurakhmanov, D, Ferreira, P A, Strasser, S I, Urbanek, P, Moreno, C, Streinu-Cercel, A, Verheyen, A, Iraqi, W, DeMasi, R, Hill, A, Läuffer, J M, Lonjon-Domanec, I, Wedemeyer, H

Volltext

The long-term prospective study of patients with liver cirrhosis after elimination of the hepatitis C virus von Nabatchikova, E. A., Abdurakhmanov, D. T., Nikulkina, E. N., Rozina, T. P., Tanaschuk, E. L., Nikiforova, N. V., Adonyeva, V. S., Moiseev, S. V.

Volltext

Antiviral therapy of chronic hepatitis C: 30 years success story von Abdurakhmanov, D T, Rozina, T P, Nikulkina, E N, Burnevich, E Z, Tanashuk, E L, Severov, M V, Filatova, A L, Milovanova, S Yu, Karpov, V V, Moiseev, S V

Volltext

Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B von Ibragimov, E K, Abdurakhmanov, D T, Rozina, T P, Nikulkina, E N, Tanaschuk, E L, Odintsov, A V, Panevkina, S V, Moiseev, S V

Volltext

HEPATITIS B VIRUS AND RHEUMATIC DISEASES von Belov, B. S., Abdurakhmanov, D. T.

Volltext

Important problems in the diagnosis and treatment of primary sclerosing cholangitis (based on the Russian consensus on diagnosis and treatment autoimmune hepatitis. Moscow, 2018) von Vinnitskaya, E V, Abdulkhakov, S R, Abdurakhmanov, D T, Alikhanov, R B, Bakulin, I G, Belousova, E A, Bueverov, A O, Burnevitch, E Z, Efanov, M G, Eremina, E Yu, Ignatova, Т М, Ilchenko, L Yu, Karmazanovsky, G G, Knyazev, O V, Kulezneva, Yu V, Lopatkina, T N, Nekrasova, T P, Nikitin, I G, Pavlenko, V V, Parfenov, A I, Podymova, S D, Raichelson, K L, Reisis, A R, Sayfutdinov, R G, Skazyvaeva, E V, Syutkin, V E, Khomeriki, S G, Haimenova, T Yu, Sandler, Yu G

Volltext

P1210 PREDICTORS OF SVR24 FOR 1078 PATIENTS WITH SEVERE FIBROSIS OR COMPENSATED CIRRHOSIS: THE INTERNATIONAL TELAPREVIR ACCESS PROGRAM von Colombo, M, Strasser, S.I, Moreno, C, Ferreira, P.A, Urbanek, P, Fernández, I, Abdurakhmanov, D, Streinu-Cercel, A, Verheyen, A, Iraqi, W, Demasi, R, Hill, A, Lonjon-Domanec, I, Wedemeyer, H

Volltext

P1212 USE OF BASELINE FIBROSCAN TO PREDICT EFFICACY AND SAFETY OF TREATMENT FOR 1143 PATIENTS IN THE TELAPREVIR EARLY ACCESS PROGRAMME von Wedemeyer, H, Colombo, M, Strasser, S.I, Ferreira, P.A, Urbanek, P, Fernandez, I, Abdurakhmanov, D, Streinu-Cercel, A, Beeldens, F, Iraqi, W, Demasi, R, Hill, A, Lonjon-Domanec, I, Moreno, C

Volltext

Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemic vasculitis: Results of a long-term follow-up von Gavrisheva, S. V., Abdurakhmanov, D. T., Bulanov, N. M., Tanashhuk, E. L., Rozina, T. P., Nikulkina, E. N., Milovanova, S. Yu, Nabatchikova, E. A., Filatova, A. L., Starostina, E. E., Krasnova, T. N., Moiseev, S. V.

Volltext

Synthesis and Biological Activity of 1,11-bis(6,7-Methylenedioxy- and 6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinolin-1-YL)Undecanes von Terent′eva, E. O., Saidov, A. Sh, Khashimova, Z. S., Tseomashko, N. E., Sasmakov, S. A., Abdurakhmanov, D. M., Vinogradova, V. I., Azimova, Sh. S.

Volltext

806 MANAGEMENT AND OUTCOMES OF ANEMIA IN THE INTERNATIONAL TELAPREVIR EARLY ACCESS PROGRAM, FOR PATIENTS WITH HEPATITIS C GENOTYPE 1 INFECTION von Colombo, M, Fernández, I, Abdurakhmanov, D, Ferreira, P.A, Strasser, S, Urbanek, P, Moreno, C, Streinu-Cercel, A, Beeldens, F, Iraqi, W, DeMasi, R, Hill, A, Läuffer, J.M, Lonjon-Domanec, I, Wedemeyer, H

Volltext

Liver fibrosis assessment by transient elastography in patients with liver cirrhosis after hepatitis C virus eradication von Nabatchikova, E. A., Abdurakhmanov, D. T., Nikulkina, E. N., Rozina, T. P., Tanaschuk, E. L., Moiseev, S. V.

Volltext

The antimicrobial activity and toxicity od alkyltetrahydroisoquinolones von Terenteva, E., Sasmakov, S., Azimov, S., Vinogradova, V., Abdurakhmanov, D., Khashimova, Z., Saidov, A.

Volltext

Antiviral therapy of chronic hepatitis C: 30 years success story von Abdurakhmanov, D T, Rozina, T P, Nikulkina, E N, Burnevich, E Z, Tanashuk, E L, Severov, M V, Filatova, A L, Milovanova, S Y, Karpov, V V, Moiseev, S V

Volltext

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II) von Zeuzem, S., Flisiak, R., Vierling, J. M., Mazur, W., Thongsawat, S., Gould, M., Hsu, S.‐J., Buggisch, P., Mutimer, D., Nault, B., Merz, M., Griffel, L. H., Tanno, Hugo, Bessone, Fernando, Terg, Ruben, Frider, Bernardo, Bertuzzi, Romina, Zekry, Amany, Weltman, Martin, George, Jacob, Crawford, Darrell, Moreno, Christophe, Reynaert, Hendrik, Lee, Samuel, Ramji, Alnoor, Tam, Edward, Marotta, Paul, Yoshida, Eric, Samuel, Didier, Alric, Laurent, Goeser, Tobias, Zeuzem, Stefan, Berg, Thomas, Rasenack, Jens, Tsang, Owen, Hui, Aric Josun, Makara, Mihaly, Gervain, Judit, Varga, Marta, Horvath, Gabor, Hunyady, Bela, Vincze, Aron, Gaeta, Giovanni Battista, Alberti, Alfredo, Colombo, Massimo, Andreone, Pietro, Picciotto, Antonino, Sacchi, Paolo, Invernizzi, Pietro, Lee, Younjae, Han, Sangyoung, Lim, Youngsuk, Hwang, Seonggyu, Maldonado, Hector, Flisiak, Robert, Jablkowski, Maciej, Prelipcean, Cristina, Musa, Manuela, Manuc, Mircea, Tanasescu, Coman, Dumitrascu, Dan, Nikitin, Igor, Znoyko, Olga, Ferret, Maria Buti, Gomez, Manuel Romero, Diago, Moises, Calleja, Jose Luis, Hsu, Shih‐Jer, Hu, Tsung‐Hui, Peng, Cheng‐Yuan, Chen, Chi‐Yi, Sukeepaisarnjaroen, Wattana, Tanwandee, Tawesak, Komolmit, Piyawat, Agarwal, Kosh, Mutimer, David, Brown, Ashley, McPherson, Stuart, Poulos, John, Rustgi, Vinod, Lyche, Kip, Karnam, Umaprasanna, Person, John, O'Leary, Jacqueline, Lawitz, Eric, Pound, David, Scarsella, Anthony, Thuluvath, Paul, Mailliard, Mark, Shiffman, Mitchell, Jacobson, Ira, Bacon, Bruce, Dimitroff, James, Reindollar, Robert, Godofsky, Eliot, Van, Kinh Nguyen, Dao, Long, Huu, Hoang Bui, Minh, Yen Lam, Thanh, Ly

Volltext

PS-156 - Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use von Gane, E., Seto, W.-K., Janssen, H., Caruntu, F.A., Kim, H.J., Abdurakhmanov, D., Nishiguchi, S., Andrzej, H., Bae, H., Mo, S., Suri, V., Gaggar, A., Flaherty, J.F., Kao, J.-H., Brunetto, M., Ferret, M.B.

Volltext

Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use von Gane, E., Seto, W.-K., Janssen, H., Caruntu, F.A., Kim, H.J., Abdurakhmanov, D., Nishiguchi, S., Andrzej, H., Bae, H., Mo, S., Suri, V., Gaggar, A., Flaherty, J.F., Kao, J.-H., Brunetto, M., Ferret, M.B.

Volltext

431 SVR RATES ARE HIGHER AMONG HCV G1 PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN (LDL) LEVELS WHEN TREATED WITH INTENSIFIED DOSES OF PEGINTERFERON ALFA-2A (PEGASYS® ) PLUS RIBA... von Harrison, S.A, Abdurakhmanov, D, Shiftman, M.L, Bakulin, I, Mazur, W, Rodriguez-Torres, M, Silva, G.F, Cheinquer, H, Messinger, D, Mckenna, M, Tatsch, F, Reddy, K.R

Volltext

264 INTENSIFIED DOSES OF PEGINTERFERON ALFA-2A AND/OR RIBAVIRIN ARE ASSOCIATED WITH HIGHER RATES OF SVR AND LOWER RELAPSE RATES AMONG PATIENTS WITH METABOLIC SYNDROME von Harrison, S.A, Shiffman, M.L, Rodriguez-Torres, M, Abdurakhmanov, D, Silva, G.F, Stanciu, C, Mazur, W, Feinman, S.V, Moreno, C, McKenna, M, Messinger, D, Teitz, A, Reddy, K.R

Volltext

292 IMPACT OF HIGHER DOSES OF PEGINTERFERON ALFA-2A AND RIBAVIRIN ON RVR, CEVR AND SVR IN HCV G1 PATIENTS WITH VIRAL LOADS ≥400,000 IU/ML WEIGHING ≥85 kg von Reddy, K.R, Shiffman, M.L, Rodriguez-Torres, M, Abdurakhmanov, D, Bakulin, I, Silva, G.F, Cheinquer, H, Rabbia, M, McKenna, M, Tietz, A, Harrison, S.A

Volltext